Metronomic Chemotherapy Regimens Using Microtubule-Targeting Agents: Mechanisms of Action, Preclinical Activity and Future Developments

Abstract

Microtubule-targeting agents (MTAs) are amongst the most successful chemotherapeutic drugs commonly used in the clinic for the treatment of human cancers. Although originally administered at or close to the maximum tolerated dose once every 3 weeks, the discovery of their potent antiangiogenic properties at the end of the 1990s has led to the re-evaluation of treatment protocols. Nowadays, MTAs are often administered at lower doses either weekly or even more frequently following a metronomic schedule, thus leading to increased effi cacy and decreased toxicity. In this chapter, we present an overview of the in vitro and

Successful Treatment of Recurrent Unresectable Oral Cancer with Sequential Targeted Therapy, Surgery, and Metronomic Chemotherapy

“…Even in a palliative situation, its addition to the standard combination of cisplatin and 5-fluorouracil has improved survival outcomes. 7 9 11 In situations where cisplatin is ineffective, cetuximab has similarly demonstrated a response rate of 13% as a single drug. 12 However, in developing nations with limited resources, it is not always feasible to apply this regimen.…”